|
Axl receptor signaling in MPNST; potential node for therapy
|
5K08CA160443-02
|
$170,618
|
$85,309
|
TORRES, KEILA
|
UT MD ANDERSON CANCER CTR
|
|
Cancer Center Support Grant
|
2P30CA016087-33
|
$2,278,153
|
$22,782
|
CARROLL, WILLIAM
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Cancer Center Support Grant
|
3P30CA016087-33S2
|
$31,251
|
$313
|
Carroll, William
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Cancer Center Support Grant
|
3P30CA008748-47S4
|
$12,328,495
|
$123,285
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RES
|
|
Cancer Center Support Grant
|
3P30CA008748-47S5
|
$18,456
|
$185
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RES
|
|
Cancer Center Support Grant
|
3P30CA008748-47S6
|
$238,405
|
$2,384
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RES
|
|
Cancer Center Support Grant
|
3P30CA142543-04S1
|
$75,000
|
$1,500
|
WILLSON, JAMES
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
5P30CA142543-04
|
$1,332,377
|
$26,648
|
WILLSON, JAMES
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
3P30CA091842-12S1
|
$75,000
|
$1,500
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-12S2
|
$41,666
|
$833
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-12
|
$4,195,787
|
$83,916
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Clinical and Genetic Studies of Neurofibromatosis Type 1
|
ZIA CP010144-10567
|
$156,749
|
$156,749
|
Stewart, Douglas
|
DCEG (NCI)
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-50S1
|
$108,009
|
$8,640
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-50S2
|
$75,000
|
$6,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-50S3
|
$300,000
|
$24,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-50S4
|
$170,000
|
$13,600
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-50S5
|
$125,000
|
$10,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
7P30CA006927-50
|
$3,797,655
|
$303,812
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Development of Mouse Astrocytoma Model for Preclinical Testing
|
ZIA BC 010541
|
$73,299
|
$51,309
|
Reilly, Karlyne
|
CCR (NCI)
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
ZIA BC 011470
|
$224,699
|
$44,940
|
Beutler, John
|
CCR (NCI)
|
|
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in
|
5R01CA111754-09
|
$267,627
|
$267,627
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Evaluation of NF1 as a Major Breast Cancer Driver
|
1R21CA175961-01
|
$168,200
|
$168,200
|
Schimenti, John
|
CORNELL UNIVERSITY
|
|
Exploration of Activity of RAD001 in vivo in Vestibular Schwannomas and Meningiom
|
5R01CA164295-02
|
$269,641
|
$134,821
|
Karajannis, Matthias
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Families at high risk of cancer
|
ZIA CP004410-08285
|
$1,048,784
|
$73,415
|
Caporaso, Neil
|
DCEG (NCI)
|
|
Hodgkin's families
|
ZIA CP004410-08167
|
$176,264
|
$79,319
|
Goldin, Lynn
|
DCEG (NCI)
|
|
Identification of Modifier Gene of Tumors Associated with NF1 and Astrocytoma
|
ZIA BC 010539
|
$513,092
|
$205,237
|
Reilly, Karlyne
|
CCR (NCI)
|
|
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
|
5R01CA152975-04
|
$452,070
|
$452,070
|
GIANCOTTI, FILIPPO
|
SLOAN-KETTERING INST CAN RES
|
|
Molecular Function of the Nf2 Tumor Suppressor, Merlin
|
5R01CA113733-09
|
$311,292
|
$311,292
|
MCCLATCHEY, ANDREA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Molecular Mechanisms of Proliferation and Infiltration of Astrocytoma
|
ZIA BC 010540
|
$146,598
|
$102,618
|
Reilly, Karlyne
|
CCR (NCI)
|
|
P21-activated kinase 1 and 2 as therapeutic targets of the NF1 microenvironment
|
1F31CA177182-01
|
$28,764
|
$28,764
|
KOSOFF, RACHELLE
|
UNIVERSITY OF PENNSYLVANIA
|
|
p21-Activated Kinases as New Therapeutic Targets in Neurofibromatosis Type 1
|
5R01CA142928-04
|
$379,935
|
$379,935
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Pathway Analysis in Mouse Model for Astrocytoma via Systems Biology Approach
|
ZIA BC 011240
|
$242,952
|
$48,590
|
Van Dyke, Terry
|
CCR (NCI)
|
|
Pediatric Oncology Branch Behvioral Science Core
|
ZID BC 011517
|
$753,196
|
$376,598
|
Merchant, Melinda
|
CCR (NCI)
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,012,786
|
$602,557
|
Merchant, Melinda
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$597,349
|
$119,470
|
Tessarollo, Lino
|
CCR (NCI)
|
|
SARC Sarcoma SPORE
|
5U54CA168512-02
|
$2,150,500
|
$193,545
|
POLLOCK, RAPHAEL
|
SARC
|
|
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH
|
5R01CA136573-05
|
$287,582
|
$287,582
|
RUBIN, JOSHUA
|
WASHINGTON UNIVERSITY
|
|
Study of Anti-Survival signals in NF1
|
7R01CA153354-02
|
$303,303
|
$303,303
|
CHEN, CHANGYAN
|
NORTHEASTERN UNIVERSITY
|
|
Substrate Profiling of Protein Tyrosine Phosphatases
|
5R01CA132855-05
|
$243,854
|
$73,156
|
Pei, Dehua
|
OHIO STATE UNIVERSITY
|
|
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy
|
3U01CA141549-05S1
|
$77,646
|
$25,623
|
Gutmann, David
|
WASHINGTON UNIVERSITY
|
|
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy
|
5U01CA141549-05
|
$709,767
|
$234,223
|
Gutmann, David
|
WASHINGTON UNIVERSITY
|
|
TAS::75 0849::TAS Incremental Funding
|
261200800001E-51
|
$271,391,560
|
$65,940
|
Heimbrook, David
|
SAIC-FREDERICK, INC.
|
|
The Role of p21-Activated Kinases in Malignant Mesothelioma
|
5R01CA148805-03
|
$348,165
|
$348,165
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
The Roles of Tumor Microenvironment in Neurofibroma Development and Therapeutics
|
5R01CA166593-02
|
$310,130
|
$310,130
|
Le, Lu
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
|
ZIA BC 010801
|
$724,380
|
$724,380
|
Widemann, Brigitte
|
CCR (NCI)
|
Total relevant funding to Neurofibromatosis for this search: $6,884,265
|